Rapid Dose Therapeutics Corp. DOSE
CNSX
| 08/31/2026 | 05/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -63.69% | -11.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -63.69% | -11.48% | |||
| Cost of Revenue | -70.33% | -27.34% | |||
| Gross Profit | -57.93% | 9.40% | |||
| SG&A Expenses | 21.32% | -28.92% | |||
| Depreciation & Amortization | -3.20% | 2.10% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.77% | -25.91% | |||
| Operating Income | -125.03% | 47.75% | |||
| Income Before Tax | -55.13% | 28.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -55.13% | 28.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -55.13% | 28.03% | |||
| EBIT | -125.03% | 47.75% | |||
| EBITDA | -148.79% | 50.93% | |||
| EPS Basic | -55.56% | 27.03% | |||
| Normalized Basic EPS | -52.94% | 26.09% | |||
| EPS Diluted | -55.56% | 27.03% | |||
| Normalized Diluted EPS | -52.94% | 26.09% | |||
| Average Basic Shares Outstanding | -0.22% | -0.32% | |||
| Average Diluted Shares Outstanding | -0.22% | -0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||